The US Food and Drug Administration has dealt a blow to the market value of New Jersey, USA-based oncology company Citius Pharmaceuticals (Nasdaq: CTXR).
Ahead of the opening bell on Monday, shares in the company had fallen by over a fifth, following news of a Complete Response Letter (CRL) related to its regulatory submission for denileukin diftitox, also known as Lymphir.
Citius is developing the interleukin (IL)-2-diphtheria toxin fusion protein to treat people with relapsed or refractory cutaneous T-cell lymphoma (CTCL), after at least one prior systemic therapy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze